Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 배상철 | - |
dc.date.accessioned | 2018-03-26T07:24:53Z | - |
dc.date.available | 2018-03-26T07:24:53Z | - |
dc.date.issued | 2014-10 | - |
dc.identifier.citation | Rheumatology international v.34,no.10 ,pp. 1409 - 1415 , 2014 | en_US |
dc.identifier.issn | 0172-8172 | - |
dc.identifier.uri | https://link.springer.com/article/10.1007%2Fs00296-014-3015-1 | - |
dc.identifier.uri | http://hdl.handle.net/20.500.11754/52528 | - |
dc.description.abstract | The aim of this study was to investigate whether the Fc gamma receptor 3A (FCGR3A) 158 V/F and interleukin-6 (IL-6) promoter -174 G/C polymorphisms can predict the response to biologic-based therapy in patients with rheumatoid arthritis (RA). We conducted a meta-analysis of studies on the association between the FCGR3A V/F polymorphism or the IL-6 -174 C/G polymorphism and non-responsiveness to biologic therapy in RA patients. A total of 10 studies involving 1,427 patients were considered. These studies consisted of seven studies on the FCGR3A polymorphism and three studies on the IL-6 polymorphism. Meta-analysis showed no association between the FCGR3A VV+VF genotype and non-responders to biologic therapy [odds ratio (OR) 0.881, 95 % confidence interval (CI) 0.505-1.537, p = 0.655]. However, stratification by biologic type indicated an association between the FCGR3A VV+VF genotype and non-responders to rituximab (OR 0.566, 95 % CI 0.373-0.857, p = 0.007), but no association was found in non-responders to tumor necrosis factor (TNF)-blockers (OR 1.337, 95 % CI 0.869-2.056, p = 0.186). Meta-analysis revealed no association between the IL-6 CC+CG genotype and non-responders to the biologics (OR 3.233, 95 % CI 0.766-13.64, p = 0.110). However, an association was found between the IL-6 CC+CG genotype and non-responders to anti-TNF therapy (OR 8.030, 95 % CI 1.807-33.68, p = 0.006). This meta-analysis demonstrates that FCGR3A V allele carriers show a better response to rituximab, and individuals carrying the IL-6 -174 C allele show a poorer response to anti-TNF therapy for RA. Genotyping for these polymorphisms may be a useful tool for predicting the response to biologics with respect to personalized medicine. | en_US |
dc.description.sponsorship | This study was supported in part by a grant of the Korea Healthcare technology R&D project, Ministry for Health & Welfare, Republic of Korea (HI12C1834). | en_US |
dc.language.iso | en | en_US |
dc.publisher | Springer Science + Business Media | en_US |
dc.subject | Rheumatoid arthritis | en_US |
dc.subject | Biologics | en_US |
dc.subject | FCGR3A | en_US |
dc.subject | IL-6 polymorphisms | en_US |
dc.subject | Non-responsiveness | en_US |
dc.title | Functional FCGR3A 158 V/F and IL-6-174 C/G polymorphisms predict response to biologic therapy in patients with rheumatoid arthritis: a meta-analysis | en_US |
dc.title.alternative | F and IL-6-174 C | en_US |
dc.type | Article | en_US |
dc.relation.no | 10 | - |
dc.relation.volume | 34 | - |
dc.identifier.doi | /10.1007/s00296-014-3015-1 | - |
dc.relation.page | 1409-1415 | - |
dc.relation.journal | RHEUMATOLOGY INTERNATIONAL | - |
dc.contributor.googleauthor | Lee, Young-Ho | - |
dc.contributor.googleauthor | Bae, Sang-Cheol | - |
dc.contributor.googleauthor | Song, Gwan-Gyu | - |
dc.relation.code | 2014038981 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF MEDICINE[S] | - |
dc.sector.department | DEPARTMENT OF MEDICINE | - |
dc.identifier.pid | scbae | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.